“Endoscopy First” or “Laparoscopic Cholecystectomy First” for Patients With Intermediate Risk of Choledocholithiasis

Overview

The study compares two different methods to evaluate extrahepatic bile ducts for possible stones for patients with cholecystolithiasis and intermediate risk for choledocholithiasis when laparoscopic cholecystectomy is indicated. Endosonoscopic evaluation of bile ducts and endoscopic retrograde cholangiography (ERCP) on demand are performed before laparoscopic cholecystectomy for one arm. Intraoperative cholangiography during laparoscopic cholecystectomy and postoperative ERCP on demand are administered in another arm.

Full Title of Study: “Comparison of Two Management Strategies, “Endoscopy First” and “Laparoscopic Cholecystectomy First”, for Patients With Gallbladder Stones and Intermediate Risk for Choledocholithiasis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Diagnostic
    • Masking: Single (Participant)
  • Study Primary Completion Date: December 15, 2020

Detailed Description

Use of ERCP as a diagnostic tool should be minimized as it carries considerable risk (5 to 10%) of post-procedural complications. It is noticed that adverse events occur more often to patients with low risk of choledocholithiasis. Therefore the best possible patient selection for ERCP procedure is needed. At the Centre of Abdominal Surgery of Vilnius University Hospital Santaros klinikos an original prognostic index (Vilnius University Hospital index (VUHI)) is used for evaluation of risk of choledocholithiasis. It is calculated by formula VUHI = A/30 + 0.4×B, where A - total bilirubin concentration (µmol/l), B – common bile duct (CBD) diameter measured by ultrasound exam. A retrospective study evaluated its accuracy and determined threshold values for low, intermediate and high risk groups. The intermediate risk group (risk for choledocholithiasis 25-75%) would benefit from additional examination before ERCP. Endoscopic ultrasound (EUS) and intraoperative cholangiography are less invasive procedures with high accuracy identifying common bile duct stones. Main hypothesis of the trial is that intraoperative cholangiography with ERCP on demand can shorten the duration and costs of treatment and avoid diagnostic ERCPs.

Interventions

  • Procedure: endoscopic ultrasound
    • Evaluation of bile ducts with endoscope with special ultrasonographic function
  • Procedure: intraoperative cholangiography
    • evaluation of bile ducts by injecting radiocontrast media to cystic duct during laparoscopic cholecystectomy
  • Procedure: ERCP
    • evaluation of bile ducts by injecting radiocontrast media to common bile duct via endoscope inserted to duodenum
  • Device: Ultrasound endoscope
    • Endoscope with built-in ultrasound function

Arms, Groups and Cohorts

  • Active Comparator: Endoscopy first
    • Endoscopic ultrasound is used to evaluate bile ducts. If stones in extrahepatic bile ducts are seen ERCP and stone evacuation is performed during the same anaesthesia. Laparoscopic cholecystectomy is performed after endoscopic procedures in two days.
  • Active Comparator: Cholecystectomy first
    • Laparoscopic cholecystectomy with intraoperative cholangiography is performed. If stones are found postoperative ERCP with stone evacuation is applied (during cholecystectomy if common bile duct is completely blocked or as soon as possible).

Clinical Trial Outcome Measures

Primary Measures

  • Duration of treatment
    • Time Frame: up to one month
    • duration from admission to hospital or decision to perform laparoscopic cholecystectomy to discharge in days

Secondary Measures

  • Accuracy of different management strategies
    • Time Frame: 6 to 7 months
    • Proportion of correctly diagnosed (true positive and true negative) cases in all sample
  • Technical success of interventions (IOC, EUS, ERCP)
    • Time Frame: up to one month
    • For intraoperative cholangiography: successful cannulation and contrast media injection into CBD. For endoscopic sonoscopy: successful visualisation of CBD. For ERCP: successful cannulation and contrast media injection into CBD.
  • Adverse events of interventions
    • Time Frame: up to one month
    • Bleeding, acute pancreatitis, perforation, allergic reactions
  • Costs of treatment
    • Time Frame: up to one month
    • charges of diagnostic procedures, invasive procedures, surgery, antibacterial treatment if needed and hospital charges

Participating in This Clinical Trial

Inclusion Criteria

  • patients with cholecystolithiasis when laparoscopic cholecystectomy is indicated – intermediate risk for choledocholithiasis (VUHI 2,6 – 6,9 and one of the predictors: dilated common bile duct, elevated total bilirubin or suspected stone in CBD on ultrasound) Exclusion Criteria:

  • pregnancy; – acute cholangitis; – biliary pancreatitis; – acute cholecystitis, degree II-III by Tokyo guidelines 2013; – anastomosis in upper gastrointestinal tract; – other known cholestatic hepatopancreatobiliary disease; – known or suspected hepatitis of another origin (viral, toxic, etc.); – contraindications for general anaesthesia or surgery; – IV-VI class of American Society of Anesthesiologists physical status classification; – morbid obesity (body mass index > 40); – patient's refusal to participate in the study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Vilnius University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ausra Aleknaite, Investigator – Vilnius University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.